SCHEMBL375823

SCHEMBL375823

O=[N+]([O-])c1cc2ccccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
IDO1 P14902 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
MAPK1 P28482 1/20 0.53
CYP2C19 P33261 1/20 0.53
NPC1 O15118 2/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 1/20 0.53
FLT3 P36888 1/20 0.46
CYP2A6 P11509 1/20 0.46
AOC3 Q16853 2/20 0.45
DAO P14920 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
SRD5A2 P31213 1/20 0.44
HSD17B10 Q99714 1/20 0.44
BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29381766 1.00 MAPT (0.53) MAPTIDO1NPSR1CYP1A2CYP2D6
Pyridine SCHEMBL6430496 0.88 NPC1 (0.44) MAPTIDO1NPSR1CYP1A2CYP2D6
SCHEMBL571925 0.86 MAPT (0.46) MAPTIDO1NPSR1CYP1A2CYP2D6
SCHEMBL28389620 0.77 CYP19A1 (0.59) MAPTNPC1MEN1POLBKMT2A
SCHEMBL3433118 0.77 ALDH1A1 (0.51) MAPTMEN1KMT2ACYP2A6KDM4E
SCHEMBL8872319 0.76 GAA (0.53) NPSR1CYP1A2MAPK1CYP2C19MEN1
SCHEMBL28391367 0.76 DAO (0.49) MAPTNPSR1CYP1A2CYP2D6MAPK1
SCHEMBL29548054 0.76 GRIN2D (0.53) MAPTIDO1NPSR1CYP1A2CYP2D6
SCHEMBL5200706 0.76 KDM4E (0.53) MAPTNPC1MEN1KMT2AKDM4E
SCHEMBL28395179 0.76 PIN1 (0.49) MAPTNPC1POLBKMT2AFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12535477-B2 Single-molecule electronic multiplex nanopore immunoassays for biomarker detection THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-01-27 US claimed
EP-3826960-B1 SINGLE-MOLECULE ELECTRONIC MULTIPLEX NANOPORE IMMUNOASSAYS FOR BIOMARKER DETECTION UNIV COLUMBIA (US) 2024-12-18 EP claimed
EP-4192982-A2 COMPOSITIONS AND METHODS FOR THE DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-2), INFLUENZA A, AND INFLUENZA B F. Hoffmann-La Roche AG (CH) 2023-06-14 EP claimed
CN-111646931-B Chiral 3-indolyl-3, 3' -disubstituted oxoindole compound and preparation method thereof 成都大学 2023-03-14 CN claimed
WO-2022066647-A1 USE OF CRISPR-CAS ENDONUCLEASES FOR PLANT GENOME ENGINEERING INARI AGRICULTURE TECHNOLOGY, INC. (US) 2022-03-31 WO claimed
US-20220042117-A1 COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) ROCHE MOLECULAR SYSTEMS, INC. 2022-02-10 US claimed
WO-2022029157-A2 COMPOSITIONS AND METHODS FOR THE DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-2), INFLUENZA A, AND INFLUENZA B F. HOFFMANN-LA ROCHE AG (CH) 2022-02-10 WO claimed
US-20210199641-A1 SINGLE-MOLECULE ELECTRONIC MULTIPLEX NANOPORE IMMUNOASSAYS FOR BIOMARKER DETECTION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-07-01 US claimed
EP-3826960-A1 SINGLE-MOLECULE ELECTRONIC MULTIPLEX NANOPORE IMMUNOASSAYS FOR BIOMARKER DETECTION The Trustees of Columbia University in the City of New York (US) 2021-06-02 EP claimed
CN-108689907-B Method for preparing 2-nitroindole derivative 苏州大学 2020-05-01 CN claimed
US-8198423-B2 High-risk human papillomavirus detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2012-06-12 US claimed
US-20120009564-A1 High-Risk Human Papillomavirus Detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2012-01-12 US claimed
US-20120009562-A1 High-Risk Human Papillomavirus Detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2012-01-12 US claimed
US-20120009563-A1 High-Risk Human Papillomavirus Detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2012-01-12 US claimed
US-8058423-B2 High-risk human papillomavirus detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2011-11-15 US claimed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP claimed
US-20090155773-A1 High-Risk Human Papillomavirus Detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2009-06-18 US claimed
US-7482142-B1 High-risk human papillomavirus detection ROCHE MOLECULAR SYSTEMS, INC. (US) 2009-01-27 US claimed
US-20070031870-A1 Methods and reagents for detecting target nucleic acids ROCHE MOLECULAR SYSTEMS, INC. (US) 2007-02-08 US claimed
EP-1748083-A1 Methods and reagents for detecting target nucleic acids Roche Diagnostics GmbH (DE) 2007-01-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12535477-B2 Single-molecule electronic multiplex nanopore immunoassays for biomarker detection EPCAM, CD47, SCNN1B MAPT 3154/4885IDO1 4731/4885NPSR1 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.